Sens-ID

Is it that time again? 😄 Just when you’ve caught your breath from the last conference, #ESMO2024 is right around the corner – and of course, Sens-ID will be there! Join us from September 13-17 in #Barcelona to discover our latest products: ctDNA ESR1 and PIK3CA Reference Materials – perfect for optimizing your assays. Plus, get an exclusive preview of our upcoming innovations: tumor-normal matched samples featuring an unmatched number of mutations, including SNVs, fusions, CNAs, and indels across various tumor entities. Precision oncology at its finest. Our experts Ronald Vos and Jens Beator will be on hand to help enhance accuracy in liquid biopsy, TMB, HRD, and MRD detection. 📧 Schedule a meeting: [email protected] or [email protected] #Oncology #CancerResearch #Genomics #NGS #CancerDiagnostics #Precisiononcology #precisionmedicine

The next conference with #SensID Meet our CEO and discuss possibilities to support your Biomarker studies and clinical Trials with reliable Reference materials. #ECP2024 #IVDR #LBx #MolecularDiagnostics #Genetics #Healthcare #Innovation #Cancercontrols #genotyping #FDA #precisionmedicine #genetictesting

💡A significant day for SensID and the future of personalized medicine! Today, we had the pleasure of celebrating a major milestone: The Minister of Economic Affairs of Mecklenburg-Vorpommern,Reinhard Meyer, presented us with a funding grant of approximately €1.78 million. This funding is a crucial step for our joint project with the University Medical Center Greifswald. Our goal is to develop customized control materials for NGS-based DNA methylation analysis. These materials are essential for accurate genetic diagnostics and open up new possibilities in personalized medicine. This success highlights the value of close collaboration between science and industry. Together, we are shaping the future of medical technology and contributing to the development of innovative, practical solutions. A big thank you to everyone involved who made this progress possible! #Genetics #Innovation #MedTech #EFRE #SensID #umgreifswald #universitymedicalcenter #greifswald #mv #healthcare #research #science  #oncology #genomics #SensID #cancerresearch #FDA #moleculardiagnostics #humangenetics #oncology #cancerresearch #IVDR #SensID #liquidbiopsy #molecularbiology #IVDD #IVDR #referencematerials #qcmaterials #moleculardiagnostics #liquidprofiling #precisionmedicine #diagnostics #companiondiagnostic #companiondiagnostics #pharma #personalizedmedicine #LBx #LiquidBiopsy Connect with Us: For more on SensID visit our website (www.sens-id.com) or contact [email protected]. Let's elevate diagnostic precision together!

🚀 Exciting News for Our Customers in Molecular Diagnostics! The Association for Molecular Pathology (AMP) recently released a report with recommendations to standardize the design and validation of clinical DPYD genotyping assays. These recommendations are a result of a joint consensus from leading organizations in genetics and pharmacogenetics, including: American College of Medical Genetics and Genomics (ACMG) Clinical Pharmacogenetics Implementation Consortium (CPIC) College of American Pathologists (CAP) Dutch Pharmacogenetics Working Group (DPWG) European Society for Pharmacogenomics and Personalized Therapy (ESPT) Pharmacogenomics Knowledgebase (PharmGKB) Pharmacogene Variation Consortium (PharmVar) with contributions by Victoria Pratt, @Larisa H. Cavallari, Makenzie Fulmer, PhD, FACMG, Andrea Gaedigk, Houda Hachad, Lilly Yuan Lisa Kalman, Reynold Ly, Ph.D Ann Moyer, Scott Stewart, @Amy J Turner, Ron H.N. van Schaik, Michelle Whirl-Carrillo Karen E. Weck 🎯 Purpose of the Report: Ensure the inclusion of appropriate variants in clinical DPYD assays. This genotyping can identify patients who may be at increased risk for severe fluoropyrimidine-related toxicity. 🔍 Variant Categorization: The report uses a two-tier classification system for the variants: Tier 1: Variants with well-characterized effects on protein function or gene expression, significant minor allele frequency in specific populations, available reference materials for assay validation, and technical feasibility for clinical laboratories. Tier 2: Variants that meet at least one but not all Tier 1 criteria. The recommendations exclude variants with unknown effects on protein function or gene expression and serve as a reference guide, not a restrictive list. https://lnkd.in/dTxiqyNd 🧬 Development of Recommendations: Considerations included the functional impact of variant alleles, allele frequencies in multiethnic populations, availability of reference materials, and other technical aspects for PGx testing. These new standards mark an important step towards optimizing patient care through more precise and standardized genotyping assays. Stay informed and take advantage of the latest advancements in molecular diagnostics! #MolecularDiagnostics #Genetics #Pharmacogenetics #Healthcare #Innovation #Cancercontrols #SensID #DPYD #genotyping #FDA #precisionmedicine #5fluorouracil #genetictesting

Join Us at cfDNA Dag 2024 in Utrecht! SensID is thrilled to announce our participation in the cfDNA Dag. 🚀 Discover Innovative cfDNA and MRD insights from great people like: Prof. Nitzan Rosenfeld, ed schuuring, Jeroen Hiltermann, Carmen Rubio Alarcón, Renske Steenbergen, Emine Kilic, Nico Callewaert, Manon Huibers, @Vincent de Jager and @Daan van den Broek! 🎙️ Meet Ronald Vos oldest BusDev member (in terms of business relationship with us 😉): We are pleased to announce that Ronald, will be attending the conference and is open to discussions! Engage with industry insights, discuss the latest trends, and explore collaboration opportunities directly with our team. 📅 Schedule a Meeting: secure your time with Ronald Vos, book a meeting slot by reaching out to us at [email protected]. We look forward to connecting with you at ESHG! 🔗 Stay Connected: Follow our LinkedIn page for real-time updates, live coverage from the event, and exclusive insights. Let's shape the future of molecular pathology together! #cfDNA #MolecularPathology #DiagnosticsInnovation #PrecisionMedicine #fdaregistered #oncology #genomics #sensid #cancerresearch #FDA #moleculardiagnostics #humangenetics #oncology #cancerresearch #IVDR #SensID #liquidbiopsy #molecularbiology #IVDD #referencematerials #qcmaterials #moleculardiagnostics #liquidprofiling #precisionmedicine #diagnostics #companiondiagnostic #companiondiagnostics #pharma #personalizedmedicine #NGS #MRD #DPYD #SensID

Join Us at EACR 2024 in Rotterdam! SensID is thrilled to announce our participation in the EACR conference. 🚀 Discover Innovative Diagnostics: Be part of the future of diagnostics with SensID! Explore our cutting-edge solutions designed to elevate molecular pathology. From advancements in molecular diagnostics to precision medicine applications, SensID is at the forefront of driving innovation in the field. 🎙️ Meet Ronald Vos our oldest BusDev member (in terms of business relationship with us 😉): We are pleased to announce that our Ronald, will be attending the conference and is open to discussions! Engage with industry insights, discuss the latest trends, and explore collaboration opportunities directly with our team. 📅 Schedule a Meeting: secure your time with Ronald, book a meeting slot by reaching out to us at [email protected]. We look forward to connecting with you at ESHG! 🔗 Stay Connected: Follow our LinkedIn page for real-time updates, live coverage from the event, and exclusive insights. Let's shape the future of molecular pathology together! #EACR24 #MolecularPathology #DiagnosticsInnovation #PrecisionMedicine #fdaregistered #oncology #genomics #sensid #cancerresearch #FDA #moleculardiagnostics #humangenetics #oncology #cancerresearch #IVDR #SensID #liquidbiopsy #molecularbiology #IVDD #referencematerials #qcmaterials #moleculardiagnostics #liquidprofiling #precisionmedicine #diagnostics #companiondiagnostic #companiondiagnostics #pharma #personalizedmedicine #NGS #MRD #DPYD

Join Us at EACR 2024 in Rotterdam! SensID is thrilled to announce our participation in the EACR conference. 🚀 Discover Innovative Diagnostics: Be part of the future of diagnostics with SensID! Explore our cutting-edge solutions designed to elevate molecular pathology. From advancements in molecular diagnostics to precision medicine applications, SensID is at the forefront of driving innovation in the field. 🎙️ Meet Ronald Vos our oldest BusDev member (in terms of business relationship with us 😉): We are pleased to announce that our Ronald, will be attending the conference and is open to discussions! Engage with industry insights, discuss the latest trends, and explore collaboration opportunities directly with our team. 📅 Schedule a Meeting: secure your time with Ronald, book a meeting slot by reaching out to us at [email protected]. We look forward to connecting with you at ESHG! 🔗 Stay Connected: Follow our LinkedIn page for real-time updates, live coverage from the event, and exclusive insights. Let's shape the future of molecular pathology together! #EACR24 #MolecularPathology #DiagnosticsInnovation #PrecisionMedicine #fdaregistered #oncology #genomics #sensid #cancerresearch #FDA #moleculardiagnostics #humangenetics #oncology #cancerresearch #IVDR #SensID #liquidbiopsy #molecularbiology #IVDD #referencematerials #qcmaterials #moleculardiagnostics #liquidprofiling #precisionmedicine #diagnostics #companiondiagnostic #companiondiagnostics #pharma #personalizedmedicine #NGS #MRD #DPYD

Join Us at ESHG 2024 in BERLIN! SensID is thrilled to announce our participation in the ESHG conference. 🚀 Discover Innovative Diagnostics: Be part of the future of diagnostics with SensID! Explore our cutting-edge solutions designed to elevate molecular pathology. From advancements in molecular diagnostics to precision medicine applications, SensID is at the forefront of driving innovation in the field. 🎙️ Meet Our CBO, Jens Beator & introducing for the first time Dijana Iloska-Leyer: We are pleased to announce that our CBO, Jens together with Dijana, will be attending the conference and are open to discussions! Engage with industry insights, discuss the latest trends, and explore collaboration opportunities directly with our team. 📅 Schedule a Meeting: secure your time with Jens or Dijana, book a meeting slot by reaching out to us at [email protected] or [email protected]. We look forward to connecting with you at ESHG! 🔗 Stay Connected: Follow our LinkedIn page for real-time updates, live coverage from the event, and exclusive insights. Let's shape the future of molecular pathology together! #ESHG2024 #MolecularPathology #DiagnosticsInnovation #PrecisionMedicine #fdaregistered #oncology #genomics #sensid #cancerresearch #FDA #moleculardiagnostics #humangenetics #oncology #cancerresearch #IVDR #SensID #liquidbiopsy #molecularbiology #IVDD #referencematerials #qcmaterials #moleculardiagnostics #liquidprofiling #precisionmedicine #diagnostics #companiondiagnostic #companiondiagnostics #pharma #personalizedmedicine #NGS #MRD #DPYD

Join Us at ASCO 2024 in Chicago! SensID is thrilled to announce our participation in the upcoming ASCO conference. 🚀 Discover Innovative Diagnostics: Be part of the future of diagnostics with SensID! Explore our cutting-edge solutions designed to elevate molecular pathology. From advancements in molecular diagnostics to precision medicine applications, SensID is at the forefront of driving innovation in the field. 🎙️ Meet Our CEO, Björn Nowack: We are pleased to announce that our CEO, Björn Nowack, will be attending the conference and is open to discussions! Engage with industry insights, discuss the latest trends, and explore collaboration opportunities directly with the visionary leader guiding SensID's success. 📅 Schedule a Meeting: secure your time with Björn Nowack, book a meeting slot by reaching out to us at [email protected] We look forward to connecting with you at ASCO! 🔗 Stay Connected: Follow our LinkedIn page for real-time updates, live coverage from the event, and exclusive insights. Let's shape the future of molecular pathology together! #ASCO24 #MolecularPathology #DiagnosticsInnovation #PrecisionMedicine #fdaregistered #oncology #genomics #sensid #cancerresearch #FDA #moleculardiagnostics #humangenetics #oncology #cancerresearch #IVDR #SensID #liquidbiopsy #molecularbiology #IVDD #referencematerials #qcmaterials #moleculardiagnostics #liquidprofiling #precisionmedicine #diagnostics #companiondiagnostic #companiondiagnostics #pharma #personalizedmedicine #NGS #MRD

If #chemotherapy is about saving lives, make sure you indeed save lives. 3 % of the population has a mutation on the #DPYD gene and could die from the adverse drug reaction. So test your patients and use a #control from SensID GmbH , in the US exclusively available via CancerControls